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IMPLANTABLE CONTROLLED RELEASE
DEVICE TO DELIVER DRUGS DIRECTLY
TO AN INTERNAL PORTION OF THE BODY

associated With cyclosporine A treatment of uveitis, While

maintaining the advantageous therapeutic properties of this

This application is a Continuation-in-Part of application
Ser. No. 08/534,854 ?led Sep. 27, 1995 noW U.S. Pat. No.

miZed by delivering the drug locally. Although direct intra
vitreal injection prevents experimental autoimmune uveitis

5,773,019.

(EAU), repeated injection is not a practical mode of admin

treatment.

The systemic toxicity of cyclosporine A may be mini

istration.
Due to the risks that certain drugs impose, researchers

TECHNICAL FIELD

The present invention relates to a simple and implantable
sustained release drug delivery device With an inner core
containing an effective amount of a loW solubility agent

covered by a non-bioerodible polymer coating layer that is
permeable to the loW solubility agent. Also, the polymer
coating layer holds the drug in the correct anatomic position
and essentially prevents disintegration of the drug core While

10

15

relates to implantable pellets for veterinary use comprising

for treating a mammal to obtain a desired local or systemic

a bioactive material such as somatotropin coated With a

physiological or pharmacological effect by surgically
20

BACKGROUND
Uveitis is a disease of the eye Which can be located

throughout the eye including the posterior and anterior
chambers of the eye as Well as the vitreous body. Uveitis, the
in?ammation of the uvea, is responsible for about 10% of

25

the visual impairment in the United States.

polyvinyl alcohol polymer to prolong the release of the
bioactive material after implantation. Parenteral administra
tion of the coated pellet is by subcutaneous implantation and
may be accomplished surgically or by injecting small pellets
through a needle. HoWever, the Castillo patent does not
teach that the polyvinyl alcohol polymer should be heated to
temperatures greater than about 100° C. to induce changes
in the crystal structure of the polymer to render it nonerod
ible. Somatotropins are heat sensitive and rapidly decom
pose on heating above 100° C. so such heating Would be

Panuveitis refers to in?ammation of the entire uveal

(vascular) layer of the eye. Posterior uveitis generally refers

rate of incorporated drugs. HoWever, these systems fail to
achieve the surprising and unexpected results obtained by
the present invention.
For example, US. Pat. No. 5,091,185 to Castillo et al.

not signi?cantly impairing the drug release rate. A method
implanting the device into a mammal in need of treatment is
also disclosed.

have developed systems for administering such drugs to aid
in the treatment of ailments and diseases. The systems have
been designed largely to reduce and to control the release

30

impractical for the systems described in the Castillo patent.

to chorioretinitis and anterior uveitis refers to iridocyclitis.

U.S. Pat No. 4,300,557 to Refojo et al. relates to an

The in?ammatory products, that is, cells, ?brin, excess

improved process for dispensing a lipid-soluble, labile drug

protein, of these in?ammations are commonly found in the
?uid spaces of the eye including the anterior chamber,

by diffusion from an implantable silicon capsule to a site
Within an animal body being treated With the drug, Wherein
the silicon capsule is provided With a tube sealed at its distal
end and through the interior Wall of Which is cut a longitu
dinal slit of 1 to 1.5 mm for ?lling the capsule folloWing

posterior chamber and vitreous space as Well as the tissue 35
involved in the in?ammatory response. Uveitis may occur
folloWing surgical or traumatic injury to the eye, as a
implantation. The capsule is surgically implanted near the
component of an autoimmune disorder such as rheumatoid

site being treated so that the tube is accessible for ?lling

arthritis, Behcet’s disease, ankylosing spondylitis,
sarcoidosis, as an isolated immune mediated ocular disorder,

40

Without further surgical procedures. In another aspect of the
invention, a drug is dispensed at a constant rate through an

i.e., pars planitis, iridodyclitis etc., unassociated With knoWn
etiologies, and folloWing certain systemic diseases Which

expandable, silicon microballoon implanted periocularly to

cause antibody-antigen complexes to be deposited in uveal
tissues. Together these disorders represent non-infectious

an intraocular site Within an animal body.
U.S. Pat No. 4,649,047 to KasWan relates to a method for

uveitities.
Cyclosporine A, a 1.2 kd cyclic peptide Which is essen

45

the treatment of, for example, uveitis occurring throughout
the globe of the eye, by topical administration of cyclospo
rine to the eye.
U.S. Pat No. 4,923,699 to Kaufman discloses an eye

tially insoluble in Water effectively inhibits the development
of experimentally induced uveitis. In human trials, cyclospo
rine A has been shoWn to be effective in treating chronic

treatment system Wherein three dimensional particles of

uveitis, especially that associated With Behcet’s disease.

serious draWbacks. Cyclosporine A used systemically has

bioerodible material of a speci?c siZe Which are suspended
in a liquid carrier or ointment carrier having a pH acceptable
to the eye are delivered topically to the eye. Various agents

also been associated With a high incidence of renal toxicity,

may be added to increase viscosity, promote suspension

Unfortunately, systemic therapy With cyclosporine A has

and/or improve ocular compatibility.

some cases of hepatotoxicity, hypertension, and an increased

incidence of opportunistic infections. The systemic side

55

effects of cyclosporine A are so severe and so common that
its use to treat life-threatening or in some cases severe

sight-threatening disease is not recommended. The systemic
toxicity is such that the National Eye Institute has recom
mended that, for uveitis in?icting one eye, cyclosporine
should not be administered. Finally, a systemic application
of cyclosporine A is limited by its prohibitive cost. Also, it
should be noted that because of poor ocular availability,
topical delivery does not result in the obtention of therapeu
tic levels of the drug in the back of the eye.
Accordingly, there exists a strong need for the elimination
of the undesirable physiological and economic problems

U.S. Pat No. 3,832,252 to Higuchi et al. relates to a drug
delivery device comprising an inner solid matrix With solid

particles of drug dispersed therethrough. Any solid material
chemically compatible With the drug and permeable to
passage of the drug by diffusion can be employed.
60

U.S. Pat No. 4,309,996 to TheeuWes relates to a system

comprising a microporous diffuser for delivering a bene?cial
agent to a ?uid environment of use at a Zero order rate for

an increased length of time at that rate. The system consists
65

essentially of a microporous Wall, or a part microporous part
semi-permeable Wall, surrounding a compartment having a
space containing the agent separated by a partition from a
space containing an expandable entity.

6,001,386
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Another object of the present invention is to provide a
means of achieving and maintaining therapeutic levels of
trans retinoic acid, cis retinoic acid and other related retinoid
compounds in the eye.
The above and other objects of the invention Will become
readily apparent to those of skill in the relevant art from the

US. Pat No. 4,309,776 to Berguer relates to an intravas

cular implantation device having a chamber for containing
transplanted cells that is implanted in a Wall of a blood
vessel or to be implanted betWeen an artery and a vein in a

Wall of each for the purpose of introducing hormonal
components into the bloodstream of a human being. It is
disclosed that the material of Which the chamber-forming

folloWing detailed description and ?gures, Wherein only the

device is made must be tolerated in a blood vessel Without

preferred embodiments of the invention are shoWn and

causing thrombosis and should permit the choice of various

degrees of porosity.

10

US. Pat No. 4,973,304 to Graham et al. relates to devices
Which have use in medical or veterinary application as
implants or as inserts. The devices can be implanted surgi

the invention.

cally into the body or introduced into a body cavity of a
human patient or an animal such that the active substance 15

diffuses out of the device through hydrogel WindoWs into the
surrounding body region. The device may be in the form of
a tube of Water-permeable material having at least one port
in the tube Wall.
The above described systems and devices are intended to

FIG. 1 is an enlarged vieW of an embodiment of the

20

certain physiological or pharmacological effects. HoWever,
there are many disadvantages associated With their use. The
25

sustained release drug delivery device shoWing inner drug

release of a drug to a patient to obtain a desired local or
30

FIG. 4 is an enlarged vieW of an embodiment of the

sustained release drug delivery device showing inner drug
35

surface area, the present invention reduces ?uctuations in
release characteristics. In one embodiment, ?uctuations

40

caused by changes in the composition of the bathing ?uid are

FIG. 6 is an enlarged vieW of an embodiment of the

In one embodiment, the device includes an inner core 45

and a non-erodible polymer coating layer, the polymer layer
being permeable to the loW solubility agent, Wherein the
polymer coating layer partially or completely covers the

a means for attachment.

FIG. 7 shoWs a graph indicating that 0.5% albumin
uncoated retinoic acid pellets release signi?cantly faster than

inner core.

Another object of the present invention is to provide a
method for treating a mammal, e.g., a human, to obtain a

55

desired and alloWing the agent to pass through the polymer

60

lar opaci?cation.

retinoic acid in the devices according to the invention.
FIG. 8 shoWs clearance of cyclosporine from the vitreous
folloWing a 1 pg injection.
FIG. 9 shoWs clearance of cyclosporine from the vitreous
folloWing a 10 pg injection.
FIG. 10 shoWs tissue levels of cyclosporine folloWing a
10 pg injection into the midvitreous.
FIG. 11 shoWs vitreous concentration of cyclosporine
folloWing device implantation measured over 6 months.

FIG. 12 shoWs tissue levels of cyclosporine folloWing
device implantation measured over 6 months. Note rela

An additional object of the present invention is to provide
an ocular delivery system that could be applied to an
intraocular lens to prevent in?ammation or posterior capsu

sustained release drug delivery device shoWing inner drug
core, permeable polymer coating layer and an extension of
the polymer coating layer containing a backing material as

comprising an effective amount of a loW solubility agent,

coating layer to the desired area of treatment.
A further object of the invention is to provide an ocular
device suitable for direct implantation into the eye. Such
devices of the present invention are surprisingly found to
provide sustained release controlled release of various com
positions to treat the eye Without risk of detrimental side
effects.

sustained release drug delivery device shoWing inner drug
core, permeable polymer coating layer and an extension of
the polymer coating layer containing a backing material as
a means for attachment.

also eliminated.

desired local or systemic physiological or pharmacological
effect. The method includes securing the sustained release
drug delivery device at an area Where release of the agent is

core, permeable polymer coating layer and an extension of
the polymer coating layer containing a support ring as a
means for attachment Wherein the support ring forms a loop
through Which a suture can be passed.
FIG. 5 is an enlarged vieW of an embodiment of the

area Without requiring additional invasions into the region.
Moreover, the present invention is designed to hold the loW
solubility agent in the correct anatomic location and to

prevent disintegration of the inner core. By maintaining

means for attachment Wherein the support ring alloWs
enough space for a suture to be passed betWeen the drug core

and the support ring.

Therefore, it is an object of this invention to provide a
device suitable for the controlled and sustained release of a
composition effective in obtaining a desired local or sys
once implanted, gives a continuous release to an affected

and an extension of the polymer coating layer as a means for
attachment.
FIG. 3 is an enlarged vieW of an embodiment of the

core, permeable polymer coating layer and an extension of
the polymer coating layer containing a support ring as a

systemic physiological or pharmacological effect.

temic physiological or pharmacological effect and Which,

FIG. 2 is an enlarged vieW of an embodiment of the

sustained release drug delivery device shoWing inner drug
core, permeable polymer coating of the present invention

patients at a desired local or systemic level for obtaining

DISCLOSURE OF THE INVENTION

BRIEF DESCRIPTION OF DRAWINGS

sustained release drug delivery device shoWing inner drug
core and permeable polymer coating.

provide sustained release of drugs effective in treating

need for a better release system is especially signi?cant in
the treatment of uveitis. Thus, there remains a long-felt need
in the art for an improved device for providing sustained

described, simply by Way of illustration of the best mode of
carrying out the invention. As is readily recogniZed the
invention is capable of modi?cations Within the skill of the
relevant art Without departing from the spirit and scope of

65

tively high levels in the lens. Bars represent SEM.
FIG. 13 shoWs ERG data demonstrating decrease in
scotopic b-Wave amplitude. Data represented as the ratio
b-Wave amplitude in drug eye to b-Wave amplitude in
control eye. Bars represent SEM.

6,001,386
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Material that may be suitable for fabricating the polymer
coating layer of the device include naturally occurring or
synthetic materials that are biologically compatible With
bodily ?uids and eye tissues, and essentially insoluble in

FIG. 14 shows ERG data demonstrating recovery of ERG

following removal of the sustained release device containing
cyclosporine. Data represented as the ratio b-Wave ampli
tude in drug eye to b-Wave amplitude in control eye. Bars
represent SEM.

bodily ?uids With Which the material Will come in contact.

In addition, the suitable materials essentially prevent inter

FIG. 15 shoWs ERG data in the monkey over 6 months
demonstrates no evidence of retinal toxicity. Bars represent
SEM.
DESCRIPTION OF THE INVENTION

action betWeen the loW solubility agent in the inner core of

the device and proteinaceous components in the bodily ?uid.
10

The present inventors have surprisingly and unexpectedly

The use of rapidly dissolving materials or materials highly
soluble in eye ?uids or Which permit interaction betWeen the

loW solubility agent in the inner core and proteinaceous
components in the bodily ?uids are to be avoided since
dissolution of the Wall or interaction With the proteinaceous

discovered a device that is suitable for the controlled and
sustained release of an agent effective in obtaining a desired

components Would affect the constancy of drug release, as

local or systemic physiological or pharmacological effect.

Well as the capability of the device to remain in place for a

The device includes an inner core comprising an effective 15 prolonged period. Suitable polymers useful in the present
invention include polyvinyl alcohol, ethylene vinyl acetate,
amount of a loW solubility agent, and a non-bioerodible

silicone, polylactic acid, nylon, polypropylene,

polymer coating layer, the polymer layer permeable to the
loW solubility agent, Wherein the polymer coating layer

polycarbonate, cellulose, cellulose acetate, polyglycolic

covers the inner core.

Once implanted, the device gives a continuous supply of
the agent to internal regions of the body Without requiring
additional invasive penetrations into these regions. Instead,
the device remains in the body and serves as a continuous
source of the agent to the affected area. In another

embodiment, the device further comprises a means for
attachment, such as an extension of the non-erodible poly
mer coating layer, a backing member, or a support ring. In
a preferred embodiment, the device is suitable for direct

implantation into the vitreous of the eye.
The device according to the present invention permits
prolonged constant release of loW solubility agents over a

speci?c period of months (e.g., 3 months, 6 months) or years
(e.g., 1 year, 5 years, 10 years, 20 years) until the agent is
substantially used up.
Suitable loW solubility agents useful in the present inven

20

25

30

35

a preferred drug used in the delivery device.
The non-bioerodible polymer coating layer of the present
invention may completely or partially cover the inner core.

polymer coating layer as long as the pellet is protected
40

including cipro?oxacin, differentiation modulators such as
retinoids (e.g., trans-retinoic acid, cis-retinoic acid and

analogues), anti-viral agents including high molecular
Weight loW (10-mers) loW solubility anti-sense compounds,

The cyclosporines Which are useful in the practice of the
present invention may be both natural or synthetic cyclospo
rines. For example, cyclosporine A may be used in the
practice of the present invention. Other forms of cyclospo
rines (e.g., isomers) may also be used. Mixtures of at least
tWo different cyclosporines may be used. The only require
ment is that the cyclosporine possess the required activity
vis-a-vis uveitis and is of extremely loW solubility.
This device enables a large variety of drugs and other
agents to be delivered into any internal region of the body,
preferably the eye. Cyclosporine A in loW solubility form is

In this regard, any portion of the surface area of the inner
core up to and including 100% may be coated With the

tion include immune response modi?ers such as cyclospo
rine A and FK 506, corticosteroids such as dexamethasone
and triamcinolone acetonide, angiostatic steroids such as

trihydroxy steroid, anti-parasitic agents such as atovaquone,
anti-glaucoma agents such as ethacrynic acid, antibiotics

acid, polylactic glycolic acid, cellulose esters or polyether
sulfone. The polymer coating layer is non-bioerodible and is
permeable to the loW solubility agent Without being release
rate limiting.

against disintegration, prevented from being physically dis
placed from its required site, and as long as the polymer
coating layer does not adversely retard the release rate.
The method for treating a mammal to obtain a desired

local or systemic physiological or pharmacological effect
45

includes surgically implanting the sustained release drug
delivery device of the present invention into the mammal
and alloWing agent to pass through the device to come in

anti-cancer agents such as BCNU, nonsteroidal anti

in?ammatory agents such as indomethacin and ?urbiprofen,

codrugs including loW solubility codrugs of salts or conju
gates of synergistic pharmacological agents such as suramin/

direct contact With the mammal.

amiloride or 5-FU/THS, and combinations thereof. The

administered to a mammal via any route of administration
knoWn in the art. Such routes of administration include

The drug delivery device of the present invention may be

compounds that may be employed in the practice of the
present invention should be in loW solubility form. Refer

intraocular, intraarticular, subcutaneous, vaginal,
intramuscular, intraperitoneal, intranasal, dermal, and the

ence may be made to any standard pharmaceutical textbook
for the procedures to obtain a loW solubility form of a drug.

By “loW solubility”, it is meant a solubility less than about
10 pg of compound per 1 ml (of Water at a temperature of
25° C. as measured by procedures set forth in the 1995

like. In addition, one or more of the devices may be
55 administered at one time or more than one agent may be

included in the inner core.

The drug delivery device of the present invention is
particularly suitable for direct surgical implantation into the

USP). This includes compounds Which are slightly soluble

(about 0.01 pg/ml-about 0.001 pig/ml), very slightly
insoluble (about 0.001 pg/ml-about 0.0001 pig/ml) and prac
tically insoluble or insoluble compounds (less than about
0.0001 pig/ml).
Examples of compounds having a loW solubility include,

60

but are not limited to, erythromycin, levodopa,

methotrexate, chloroquin, cholothiaZide, ?uocinolone
acetonide, rifampin, acetomoliZide, theophyllyne, and tetra
cane.

eye.
The entire structure is made of material Which is com
patible With the human tissue With Which it comes in contact.
In a preferred embodiment the material of the device is
polyvinyl alcohol. If a backing member is present in a

preferred embodiment, the backing member may be com
65

posed of any material tolerated by the human body, prefer

ably ethylene vinyl acetate, Te?on, silicone, silastic and

nylon.

6,001,386
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These methods of administration and technique for their
preparation are Well known by those of ordinary skill in the
art. Techniques for their preparation are set forth in Rem

As can be seen from the graph depicted in FIG. 7, in 0.5%

albumin uncoated retinoic acid pellets release signi?cantly
faster than retinoic acid in the devices. This is due in part to

ington’s Pharmaceutical Sciences.

the coating preventing small particles of poWder from ?ak

The drug delivery device may be administered for a
sufficient period of time and under conditions to alloW

ing from the surface and increasing the surface area. Increas

treatment of the disease state of concern.

rate of retinoic acid from the pellets but has minimal effect

ing the albumin concentration greatly increases the release
on release from the device.

For localiZed drug delivery, the device may be surgically
implanted at or near the site of action. This is the case for

devices of the present invention used in treating ocular
conditions, primary tumors, rheumatic and arthritic
conditions, and chronic pain. The device may be used to
control the rate of drug delivery to any internal region of the

10

concentration of the vitreous and aqueous can increase by a

factor of 40. Without the release stabiliZing properties of the
device this Would cause a huge increase in release rate With
unforetold consequences.

body.
For systemic relief, the devices may be implanted
subcutaneously, intramuscularly or intraperitoneally. This is

15

EXAMPLE 4

the case When devices are to give sustained systemic levels.

The folloWing examples are merely illustrative of the
present invention and they should not be considered as
limiting the scope of the invention in any Way, as these

This stabiliZation is important in many diseases, espe
cially ophthalmic diseases. In some eye diseases the albumin
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All animal procedures Were performed using NeW
Zealand albino rabbits of either sex Weighing approximately
2 kg and adhered to the guidelines set forth by the Asso
ciation for Research in Vision and Ophthalmology for ani
mal use in research.

examples and other equivalents Will become more apparent
to those skilled in the art in light of the present disclosure.

TWenty four animals (Group 1) Were used. Cyclosporine
Was mixed into stock solutions of 50:50 ethanol:Water at a

EXAMPLE 1

A(obtained from the National Eye Institute as a gift) coated

concentration of 1 pg/20 pl and 10 pg/20 pl. 3H-labeled
cyclosporine (1 pCi/20 pl) Was also added to the stock
solution. Animals Were anesthetiZed With ketamine (60 mg)
and xylaZine (20 mg) and the pupils Were dilated With one

in polyvinyl alcohol (PVA) (obtained from Polysciences,

drop of phenylephrine hydrochloride (2.5%) and tropicam

Inc.) and heated at 110° C. for 10 minutes. In design it
resembled FIG. 2. The device Was implanted into the vitre
ous of 3 monkeys and appeared safe. Another monkey

given through the superior rectus muscle approximately 5

Adevice according to the present invention Was prepared.
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This device Was composed of a 5 mg core of cyclosporine

ide (1%). An intravitreal injection of cyclosporine Was then
mm posterior to the limbus using a 30 gauge needle. TWelve

received an identical pellet and after 6 months Was sacri?ced

animals received a dose of 1 pg(20 pl) and 12 animals
received a dose of 10 pg(20 pl). The injection Was given into

and a sample of vitreous obtained. Analysis shoWed the
concentration of cyclosporine to be 60 ng/ml. This indicates

the midvitreous cavity and care Was taken to avoid the lens.
For the 1 pg group, 3 animals Were sacri?ced at 0.5, 3, 6 and
24 hours. For the 10 pg group, 3 animals Were sacri?ced at
0.5, 6, 24 and 48 hours. The eyes Were enucleated and then

that the system can be used to maintain therapeutic levels of

drug (in this case cyclosporine) in the eye for prolonged
periods. Due to the “soft” nature of PVA When heated to
110° C. an improved device Would contain a support ring or

backing (FIG. 4 or 6).

immediately froZen at —70° C. Tissues Were prepared for
40

EXAMPLE 2

Adevice according to the present invention Was prepared.

FolloWing a 1 pg injection the regression equation of in

This device Was composed of a 3 mm, 12 mg disc of retinoic
acid encased in silicone. It resembles FIG. 3 in appearance.

The implant Was prepared by preparing a thin ?lm of

concentration versus time for vitreous levels Was y=1.17—
45

0.15x (R2=0.99)Wh1Ch equates to a half-life of 4.2 hours and

distribution volume of 3.2 ml (FIG. 8). FolloWing the 10 pg
injection the regression equation for vitreous levels Was
y=1.75—0.058x (R2=0.99) Which equates to a half-life of

silicone. A 2.5 mm hole Was then cut through the ?lm and

the retinoic acid pellet ?xed directly over the hole using
silicone. A loop of Prolene suture Was placed over the pellet

10.8 hours and a volume of distribution of 1.7 ml (FIG. 9).

and ?xed onto the surface of the ?lm so that a “gap” of over
1 mm Was present betWeen the pellet and the suture all the

Analysis of tissue samples (FIG. 10) demonstrated relatively
high lens levels. The drug content in the lens remained high

Way around. The entire assembly Was then coated again in
silicone. These pellets Were sutured onto the surface of the
sclera in 3 rabbits and the ERGs taken every Week for 5

throughout the study period. Thirty minutes folloWing the 1

Weeks. There Was no evidence of toxicity.
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EXAMPLE 3

Pellets of retinoic acid Were prepared by compressing 2
mg of the compound in a 1.5 mm Parr Instruments Press.
Some pellets Were then coated in PVA and heated to 120° C.
and trimmed leaving a suture tab attached as shoWn in FIG.

assay as described beloW. Intravitreal half-life and volume of
distribution Were determined from regression analysis of a in
concentration versus time plot.
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pg injection the amount of cyclosporine in the vitreous Was
0.39 pg While the total drug present in all of the remaining
ocular tissue samples Was 0.27 pg. Thus the ratio of total
tissue cyclosporine to vitreous cyclosporine Was 0.69. Thirty
minutes after the 10 pg injection there Was 7 pg of cyclospo
rine in the vitreous and 0.75 pg of cyclosporine in the tissues
Which equates to a total tissue cyclosporine to vitreous

cyclosporine ratio of 0.11.

2 While other pellets Were not coated. Uncoated pellets and

devices Were immersed in 1 ml of phosphate buffer (pH 7.4)
containing 0.5% albumin at 37° C. After 24 hours the buffer
Was replaced With fresh and the amount of drug released
calculated by HPLC. After approximately 25 days buffer
containing 1.0% albumin Was added and the experiment
continued.

EXAMPLE 5

Eighteen animals (Group 2) Were used. Devices consisted
of a core of 5 mg of cyclosporine Which Wa labeled With 13.6
65

pCi 3H-cyclosporine.
The core, Which measured 2.5 mm in diameter, Was

coated With several layers of polyvinyl alcohol and then heat

